U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07324304) titled 'NWRD06 DNA Plasmid for HCC After Curative Resection.' on Dec. 23, 2025.
Brief Summary: This is a single-arm, open-label, multi-center Phase 2 clinical study to evaluate the efficacy and safety of Glypican3 (GPC3)-targeted DNA plasmid vaccine (NWRD06) in patients with GPC3-positive primary hepatocellular carcinoma after curative resection.
Study Start Date: Dec. 08, 2025
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Carcinoma (HCC)
Intervention:
BIOLOGICAL: NWRD06 administered by electroporation
DNA plasmid delivered via IM injection + electroporation using TERESA device
Recruitment Status: RECRUITING
Sponsor: Newish T...